Mounjaro is a once-weekly injectable prescription medication containing tirzepatide, used alongside diet and exercise to improve blood sugar control in adults with type 2 diabetes. It was the first FDA-approved drug to activate two gut hormone receptors simultaneously, setting it apart from older injectable diabetes medications that target only one.
How Mounjaro Works
Your gut naturally releases hormones called incretins after you eat. Two of the most important are GLP-1 and GIP, both of which signal your pancreas to produce insulin when blood sugar rises. Most injectable diabetes drugs mimic only GLP-1. Mounjaro mimics both, which is why it’s classified as a dual GIP/GLP-1 receptor agonist.
This dual action does several things at once. It boosts insulin release in response to meals, slows the rate at which your stomach empties (so sugar enters your bloodstream more gradually), and reduces appetite by signaling fullness to your brain. The GIP pathway adds something the older GLP-1-only drugs don’t: it appears to support the health of insulin-producing beta cells in the pancreas and may enhance the weight-lowering effects of GLP-1 through synergistic signaling. In animal studies, combining both hormones produced greater reductions in body weight and food intake than either hormone alone.
What Mounjaro Is Approved For
Mounjaro is FDA-approved specifically for type 2 diabetes in adults. The same active ingredient, tirzepatide, is also sold under the brand name Zepbound for chronic weight management, but the two are considered separate products with separate approvals. You should not use Mounjaro and Zepbound together, or combine Mounjaro with another GLP-1 receptor agonist.
How Well It Works
In clinical trials lasting 40 to 52 weeks, Mounjaro reduced A1c levels substantially across all doses. At the 5 mg dose, average A1c dropped by roughly 1.9 percentage points, with the 15 mg dose bringing reductions closer to 2.6 percentage points. For context, most diabetes medications lower A1c by about 0.5 to 1.5 points, so these results were unusually large.
Weight loss was also significant. Across multiple trials lasting 72 weeks, participants lost between 5% and 20.9% of their body weight depending on the dose. That means someone weighing 220 pounds could lose anywhere from 11 to 46 pounds at the higher end. Both the blood sugar and weight effects were dose-dependent, meaning higher doses generally produced bigger results.
Dosing and Titration Schedule
Mounjaro starts at a low dose and increases gradually to minimize side effects. The typical schedule looks like this:
- Weeks 1 through 4: 2.5 mg once per week (this is a starter dose, not a therapeutic dose)
- Weeks 5 onward: 5 mg once per week
- Further increases: If blood sugar remains too high after at least 4 weeks on a given dose, your prescriber can increase by 2.5 mg increments
- Maximum dose: 15 mg per week for adults, 10 mg per week for children
Each increase happens in 4-week intervals, so reaching the maximum dose takes several months. Many people find adequate blood sugar control at 5 mg or 10 mg and never need the highest dose.
How to Inject Mounjaro
Mounjaro comes in a pre-filled, single-dose pen (called the KwikPen). You don’t need to measure or draw up medication. Before your first injection, wash your hands, pull the pen cap off, and check the label to confirm the dose matches your prescription and the pen hasn’t expired. Wipe the red inner seal with an alcohol swab, attach a new pen needle by twisting it on, and remove both the outer and inner needle shields. Keep the outer shield for disposal later.
You’ll need to prime the pen before injecting. Turn the dose knob until you hear two clicks, point the needle upward, tap the cartridge gently to move any air bubbles to the top, then push and hold the knob until it stops. A small drop of medication at the needle tip confirms the pen is primed.
To inject, turn the dose knob until it stops and shows the full-dose icon. Insert the needle into your chosen injection site, push the knob in until it stops, and hold for a slow count of five before pulling the needle out. A small drop of medication on the needle tip afterward is normal and doesn’t mean you lost part of your dose.
You can inject into your stomach (at least two inches from your belly button) or the front of your thigh. If someone else is giving the injection, the back of your upper arm is also an option. Rotate your injection site each week. You can use the same general area, but pick a different spot within that area.
If You Miss a Dose
If you miss your weekly injection, take it as soon as you remember, as long as it’s been fewer than 4 days (96 hours) since the missed dose. If more than 4 days have passed, skip that dose entirely and resume on your next regularly scheduled day. Never take two doses within 3 days of each other.
Storage
Unused Mounjaro pens should be kept in the refrigerator between 36°F and 46°F (2°C to 8°C). If you need to travel or don’t have fridge access, an unused pen can stay at room temperature (up to 86°F or 30°C) for up to 30 days. Once you’ve used a pen, it can also be stored at room temperature for up to 30 days. Don’t freeze the pens, and don’t use one that’s been frozen.
Common Side Effects
Gastrointestinal symptoms are by far the most frequent side effects, especially during the first few weeks and after dose increases. In clinical trials, up to 22% of people experienced nausea, making it the most common complaint. Diarrhea affected 12% to 17% of participants, and about 1 in 10 reported vomiting. Constipation occurred in roughly 1 in 13 people, while heartburn or acid reflux was less common at about 2%.
These side effects tend to improve as your body adjusts. The slow titration schedule exists specifically to give your digestive system time to adapt. Eating smaller meals, avoiding high-fat foods, and staying hydrated can help reduce nausea during the adjustment period.
Serious Risks
Mounjaro carries an FDA boxed warning (the most serious type of safety warning) about thyroid tumors. In rat studies, tirzepatide caused thyroid C-cell tumors at doses comparable to human use. Whether this same risk applies to humans hasn’t been determined, but because the possibility can’t be ruled out, Mounjaro is not prescribed to anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. Signs to watch for include a lump or swelling in your neck, difficulty swallowing, shortness of breath, or persistent hoarseness.
Acute pancreatitis, including severe and potentially fatal forms, has also been reported in people taking Mounjaro and similar drugs. The hallmark symptom is intense abdominal pain that doesn’t go away, sometimes radiating to the back, with or without nausea and vomiting. If you develop this kind of pain, it requires immediate medical attention and Mounjaro should be stopped.